Premium
Effects of the angiotensin‐converting enzyme inhibitor enalapril on blood haematopoietic progenitors and Acetyl‐N‐Ser‐Asp‐Lys‐Pro concentrations
Author(s) -
COMTE L.,
LORGEOT V.,
VOLKOV L.,
ALLEGRAUD A.,
ALDIGIER J.C.,
PRALORAN V.
Publication year - 1997
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1046/j.1365-2362.1997.1980737.x
Subject(s) - haematopoiesis , enalapril , angiotensin converting enzyme , colony forming unit , progenitor cell , endocrinology , medicine , chemistry , cfu gm , enzyme , ace inhibitor , stem cell , pharmacology , biology , biochemistry , microbiology and biotechnology , genetics , bacteria , blood pressure
Acetyl‐N‐Ser‐Asp‐Lys‐Pro (AcSDKP) is a physiological inhibitor of the proliferation of haematopoietic stem cells. In 12 healthy volunteers treated with the angiotensin‐converting enzyme (ACE) inhibitor enalapril (20 mg day −1 for 15 days), we studied plasma and urinary AcSDKP levels, the in vitro degradation of AcSDKP by plasma ACE and the numbers of circulating haematopoietic progenitors (granulocyte‐monocytic colony forming unit: CFU‐GM; burst forming unit‐erythroid: BFU‐E; and mixed colony forming unit: CFU‐mixed). During treatment, plasma and urinary AcSDKP concentrations increased 2‐ to 5‐fold, degradation of AcSDKP was reduced, and CFU‐mixed significantly increased by 100% while BFU‐E and CFU‐GM significantly decreased by 16% and 26%, respectively. These results indicate that ACE inhibitors may be of value during chemotherapy or radiotherapy, warranting further study.